The association of statins with markers of inflammation, vasoconstriction, and coagulation was evaluated in 325 patients with abdominal aortic aneurysm with respect to statin treatment or not. Variables evaluated included routine laboratory markers, lipids, homocysteine, endothelin-1, matrix metalloproteinases (MMP)-2 and -9, and activated protein C-protein C inhibitor (APC-PCI) complex. Statin-treated patients were more often male (85% vs 75%; P = .024) and had ischemic heart disease (57% vs 19%; P < .0001). They showed lower levels of cholesterol (P < .0001), homocysteine (P = .027), MMP-9 (P = .038), and endothelin-1 (P = .005), and higher levels of APC-PCI complex (P = .042). Differences persisted in logistic regression for cholesterol (P < .0001), APC-PCI complex (P = .034), and homocysteine (P = .021). Statin-treated patients with abdominal aortic aneurysm show higher APC-PCI complex and lower homocysteine levels. Whether this translates into lower risk for aneurysm expansion or rupture will be evident from further follow-up.
Wassef M., Baxter BT, Chisholm RL, et al. Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute . J Vasc Surg. 2001;34:730-738.
2.
Vainas T., Lubbers T., Stassen F., et al. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. Circulation. 2003;107:1103-1105.
3.
Norman P., Spencer CA, Lawrence-Brown MM, Jamrovik K.C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. Circulation. 2004;110:862-866.
4.
Dawson J., Cockerhill GW, Choke E., Belli AM, Loftus I., Thompson MMAortic aneurysms secrete interleukin-6 into the circulation. J Vasc Surg. 2007;45: 350-356.
5.
Middleton RK, Lloyd GM, Bown MJ, Cooper NJ, London NJ, Sayers RDThe pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study. J Vasc Surg. 2007;45:574-580.
6.
Jones KG, Brull DJ, Brown LC, et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms . Circulation. 2001;103:2260-2265.
7.
Satoh H., Nakamura M., Satoh M., et al. Expression and localization of tumour necrosis factor-alpha and its converting enzyme in human abdominal aortic aneurysm. Clin Sci (Lond). 2004;106:301-306.
8.
Witkowska AM, Borawska MH, Gacko M.Relationship among TNF-alpha, sICAM-1, and selenium in presurgical patients with abdominal aortic aneurysms. Biol Trace Elem Res. 2006;114:31-40.
9.
Kishimoto T.The biology of interleukin-6. Blood. 1989; 74:1-10.
10.
Schönbeck U. , Libby P.CD40 signaling and plaque instability. Circ Res. 2001;89:1092-1103.
11.
Schönbeck U. , Gerdes N., Varo N., et al. Oxidized low-density lipoprotein augments and 3-hydroxy-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation. 2002;106:2888-2893.
12.
Kälsch T., Nguyen XD, Elmas E., et al. Coagulation activation and expression of CD40 ligand on platelets in vitro liposaccharide-challenge in patients with unstable angina. Int J Cardiol. 2006;111:217-223.
13.
Newby DE, Webb DJThe endothelin system in cardiovascular disease. Br Med J . 1997;314:531-532.
14.
Ikeda U., Yamamoto K., Maeda Y., Shimpo M., Kanbe T., Shimada K.Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells . Hypertension. 1997;29:65-69.
15.
Yamazumi K. , Ojiro M., Okumura H., Aikou T.An activated state of blood coagulation and fibrinolysis in patients with abdominal aortic aneurysm. Am J Surg. 1998;175:297-301.
16.
Strandberg K., Kjellberg M., Knebel R., Lilja H., Stenflo J.A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor. Thromb Haemost. 2001;86:604-610.
17.
Kölbel T., Strandberg K., Mattiasson I., Stenflo J., Lindblad B.Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms. J Vasc Surg. 2006;43:935-939.
18.
Scandinavian Simvastatin SurvivalStudy Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-1389.
19.
Downs JR, Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS . JAMA. 1998;279:1615-1622.
Vaughan CJ, Gotto AM, Basson CTThe evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000;35:1-10.
22.
Takemoto M. , Liao JKPleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
23.
Bellosta S. , Ferri N., Bernini F., Paoletti R., Corsini A.Non-lipid-related effects of statins. Ann Med. 2000;32:164-176.
24.
Strandberg TE, Vanhanen H., Tikkanen MJEffect of statins on C-reactive protein in patients with coronary artery disease. Lancet. 1999;353:118-119.
25.
Rosenson RS , Tangney CC, Casey LCInhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999;53:983-984.
26.
Ferro D., Parrotto S., Basili S., Alessandri C., Violi F.Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol. 2000;36:427-431.
27.
Ridker PM, Rifai N., Pfeffer MA, Sacks F., Braunwald E.; for the Cholesterol and Recurrent Events (CARE) investigators.Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999; 100:230-235.
28.
Undas A., Brumel-Zeidins KE, Mann KGStatins and blood coagulation. Arterioscler Thromb Vasc Biol . 2005; 25:287-294.
29.
Masamura K. , Oida K., Kanehara H., et al. Pravastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol. 2003;23:512-517.
30.
Sukhija R., Aronow WS, Sandhu R., et al. Mortality and size of abdominal aortic aneurysm at long term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol. 2006; 97:279-280.
31.
Schouten O. , van Laanen JH, Boersma E., Vidakovic R., Feringa HH, Dunkelgrun M.Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg . 2006;32:21-26.
32.
Evans J., Powell JT, Schwalbe E., Loftus IM, Thompson MMSimvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg. 2007 ;34:302-303.
33.
Esmon CTThe interactions between inflammation and coagulation. Br J Haematol. 2005;131:417-430.
34.
Nieminen T. , Knuuti J., Hämelahti P., et al. Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy. Vasc Pharmacol. 2007;47:113-117.
35.
Moroz P., Le MT, Norman PEHomocysteine and abdominal aortic aneurysms. ANZ J Surg. 2007;77:329-332.
36.
Halazun KJ, Bofkin KA, Asthana S., Evans C., Henderson M., Spark JIHyperhomocysteinaemia is associated with the rate of abdominal aortic aneurysm expansion. Eur J Vasc Endovasc Surg. 2007;33:391-394.
37.
Wagner A., Domanovits H., Holzer M., et al. Plasma endothelin in patients with acute aortic disease. Resuscitation. 2002;53:71-76.
Mraiche F., Cena J., Das D., Vollrath B.Effects of statins on vascular function of endothelin-1. Br J Pharmacol. 2005;144:715-726.
40.
Lam HC, Chu CH, Wei MC, et al. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia. Exp Biol Med. 2006;231:1010-1015.
41.
AikawaM.,RabkinE.,SugiyamaS.,etal. AnHMG-CoAreductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo, and in vitro . Circulation. 2001;103: 276-283.
42.
Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G., Franklin DP, Youkey JRThe matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J Vasc Surg. 1999 ;29: 130-138.
43.
Thompson RW , Baxter BTMMP inhibition in abdominal aortic aneurysms. Rrationale for a prospective randomized clinical trial. Ann N Y Acad Sci.1999;878: 159-178.
44.
Nagashima H. , Aoka Y., Sakomura Y., et al. Matrix metalloproteinase 2 is suppressed by trapidil, a CD40-CD40 ligand pathway inhibitor, in human abdominal aortic aneurysm wall. J Vasc Surg.2004;39:447-453.
45.
Crilly M., Bundred P., Hu X., Leckey L., Johnstone F.Gender differences in the clinical management of patients with angina pectoris: a cross-sectional survey in primary care. BMC Health Serv Res. 2007;4:142.
